GlassScriptPhysician profile
Daniel J Mollin
NPI 1588659577
$1,876.44
in general payments reported to CMS, 2019-2025
27 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $850 · 2020: $136 · 2021: $52.38 · 2022: $60.44 · 2023: $76.59 · 2024: $365 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $778.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $487.88 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $228.75 | 2019-2023 | Evenity, Prolia |
| Lilly USA, LLC | $213.41 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Abbott Laboratories | $110.29 | 2021-2025 | Freestyle Libre 3, Eterna, Proclaim |
| Daiichi Sankyo INC. | $107.94 | 2019-2025 | Injectafer |
| Astellas Pharma US INC | $107.06 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.61 | 2019-2024 | |
| Pfizer INC. | $63.25 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $49.30 | 2019-2020 | |
| Grifols USA, LLC | $48.10 | 2019-2025 | Prolastin-C Liquid |
| Amarin Pharma, INC. | $46.26 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $42.28 | 2019-2021 | |
| Abiomed | $30.51 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.57 | 2019-2020 | |
| C2n Diagnostics, LLC | $28.05 | 2025 | Precivityad2 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22.13 | 2025 | |
| Gilead Sciences, INC. | $21.77 | 2019 | |
| Dexcom, INC. | $21.20 | 2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $20.90 | 2024 | |
| Allergan, INC. | $18.16 | 2019 | |
| Shionogi INC | $17.52 | 2019 | |
| Glaxosmithkline, LLC. | $16.64 | 2022 | |
| Phadia US INC. | $15.44 | 2024 | Immunocap |
| Sanofi Pasteur INC. | $14.94 | 2019 | |
| Echosens North America, INC. | $14.91 | 2025 | Fibroscan |
| E.R. Squibb & Sons, L.L.C. | $14.59 | 2022 | |
| Exact Sciences Corporation | $13.98 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mollin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.